The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

Michael W. Weiner, Dallas P. Veitch, Paul S. Aisen, Laurel A Beckett, Nigel J. Cairns, Robert C. Green, Danielle J Harvey, Clifford R. Jack, William Jagust, John C. Morris, Ronald C. Petersen, Jennifer Salazar, Andrew J. Saykin, Leslie M. Shaw, Arthur W. Toga, John Q. Trojanowski

Research output: Contribution to journalArticlepeer-review

109 Scopus citations


Introduction: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study. Methods: ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. Results: Multimodal analyses will provide insight into AD pathophysiology and disease progression. Discussion: ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.

Original languageEnglish (US)
JournalAlzheimer's and Dementia
StateAccepted/In press - 2016


  • Alzheimer's disease
  • Amyloid phenotyping
  • Brain Health Registry
  • Centiloid method
  • Clinical trial biomarkers
  • Functional connectivity
  • Tau imaging

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Geriatrics and Gerontology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health


Dive into the research topics of 'The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement'. Together they form a unique fingerprint.

Cite this